This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 6, at 10:20 a.m. Eastern Time.
A live webcast of the presentation will be available in the Investor Relations section of the company's Web site at
http://investors.somaxon.com/events.cfm. The webcast will be accessible following conclusion of the live event and archived for approximately 30 days following the conference.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxon's product Silenor, available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.
For more information, please visit the company's web site at
The Somaxon Pharmaceuticals logo is available at
CONTACT: Tran Nguyen / CFO
Somaxon Pharmaceuticals, Inc.
Matt Sheldon/ Investor Relations